BioCentury | Jun 17, 2013
Company News

BioLineRx, Jiangsu Chia-Tai Tianqing deal

...and milestones and is also eligible for high single-digit royalties. BioLineRx in-licensed the compound from Genoscience...
BioCentury | Jun 11, 2013
Company News

BioLineRx out-licenses HCV compound to Jiangsu Chia-Tai

...high single-digit royalties. BioLineRx, which could not be reached for details, in-licensed the compound from Genoscience...
BioCentury | May 6, 2013
Clinical News

BL-8020: Phase I/II started

...initially receive 8 weeks of ribavirin monotherapy. BioLineRx has exclusive, worldwide rights to BL-8020 from Genoscience...
...a 2012 deal (see BioCentury, Jan. 30, 2012). BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX), Jerusalem, Israel Genoscience...
BioCentury | Mar 18, 2013
Clinical News

BL-8020: Phase I/II start

...in patients who failed or relapsed following standard-of-care treatment. BioLineRx has exclusive, worldwide rights from Genoscience...
...a 2012 deal (see BioCentury, Jan. 30, 2012). BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX), Jerusalem, Israel Genoscience...
BioCentury | Feb 13, 2012
Company News

BioLineRx, Genoscience, RFS deal

...BioLineRx received exclusive, worldwide rights from Genoscience and RFS Pharma to BL-8030 , an HCV NS3...
...NS3 protease inhibitor in preclinical development. BioLineRx expects to begin clinical trials in 18-24 months. Genoscience...
...upfront payments and are eligible for milestones and royalties. Details were not disclosed. Last month, Genoscience...
BioCentury | Feb 7, 2012
Company News

BioLineRx in-licenses another HCV compound

...BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) announced a deal with Genoscience (Marseille, France) and RFS Pharma LLC...
...NS3 protease inhibitor in preclinical development. BioLineRx expects to begin clinical trials in 18-24 months. Genoscience...
...payments and are eligible for milestones and royalties. Details were not disclosed. On Jan. 24, Genoscience...
BioCentury | Jan 30, 2012
Finance

Highlights of weekly biotech stock moves

...& Flow BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) jumped $2.26 (69%) to $5.55 on Tuesday after Genoscience...
BioCentury | Jan 30, 2012
Company News

BioLineRx, Genoscience deal

...for milestones plus royalties. Details were not disclosed. BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX), Jerusalem, Israel Genoscience...
BioCentury | Jan 25, 2012
Company News

BioLineRx soars on HCV deal

...BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) jumped $2.26 (69%) to $5.55 on Tuesday after Genoscience (Marseille, France...
...Marseille, France) granted BioLineRx exclusive, worldwide rights to preclinical oral HCV compound BL-8020. According to Genoscience's...
Items per page:
1 - 9 of 9
BioCentury | Jun 17, 2013
Company News

BioLineRx, Jiangsu Chia-Tai Tianqing deal

...and milestones and is also eligible for high single-digit royalties. BioLineRx in-licensed the compound from Genoscience...
BioCentury | Jun 11, 2013
Company News

BioLineRx out-licenses HCV compound to Jiangsu Chia-Tai

...high single-digit royalties. BioLineRx, which could not be reached for details, in-licensed the compound from Genoscience...
BioCentury | May 6, 2013
Clinical News

BL-8020: Phase I/II started

...initially receive 8 weeks of ribavirin monotherapy. BioLineRx has exclusive, worldwide rights to BL-8020 from Genoscience...
...a 2012 deal (see BioCentury, Jan. 30, 2012). BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX), Jerusalem, Israel Genoscience...
BioCentury | Mar 18, 2013
Clinical News

BL-8020: Phase I/II start

...in patients who failed or relapsed following standard-of-care treatment. BioLineRx has exclusive, worldwide rights from Genoscience...
...a 2012 deal (see BioCentury, Jan. 30, 2012). BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX), Jerusalem, Israel Genoscience...
BioCentury | Feb 13, 2012
Company News

BioLineRx, Genoscience, RFS deal

...BioLineRx received exclusive, worldwide rights from Genoscience and RFS Pharma to BL-8030 , an HCV NS3...
...NS3 protease inhibitor in preclinical development. BioLineRx expects to begin clinical trials in 18-24 months. Genoscience...
...upfront payments and are eligible for milestones and royalties. Details were not disclosed. Last month, Genoscience...
BioCentury | Feb 7, 2012
Company News

BioLineRx in-licenses another HCV compound

...BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) announced a deal with Genoscience (Marseille, France) and RFS Pharma LLC...
...NS3 protease inhibitor in preclinical development. BioLineRx expects to begin clinical trials in 18-24 months. Genoscience...
...payments and are eligible for milestones and royalties. Details were not disclosed. On Jan. 24, Genoscience...
BioCentury | Jan 30, 2012
Finance

Highlights of weekly biotech stock moves

...& Flow BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) jumped $2.26 (69%) to $5.55 on Tuesday after Genoscience...
BioCentury | Jan 30, 2012
Company News

BioLineRx, Genoscience deal

...for milestones plus royalties. Details were not disclosed. BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX), Jerusalem, Israel Genoscience...
BioCentury | Jan 25, 2012
Company News

BioLineRx soars on HCV deal

...BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) jumped $2.26 (69%) to $5.55 on Tuesday after Genoscience (Marseille, France...
...Marseille, France) granted BioLineRx exclusive, worldwide rights to preclinical oral HCV compound BL-8020. According to Genoscience's...
Items per page:
1 - 9 of 9